Compare Nutrien Ltd (NTR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Sanofi SA — how do they compare? Nutrien Ltd trades at $80.95 (market cap $38.47B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 2.7× Nutrien Ltd's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| NTR | SNY | |
|---|---|---|
Market Cap | $38.47B | $104.06B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $52.34 |
52-Week Low | $53.64 | $41.33 |
Enterprise Value | $50.28B | $124.09B |
Dividend Yield | 2.73% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $80.68, up 1.52% today, near the analyst high target of $81.00. The stock shows a bullish technical trend with strong moving averages, though RSI levels indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher fertilizer prices. The company maintains a moderate buy consensus with 61% of analysts recommending buys, supported by institutional accumulation like BlackRock's $220.94 million purchase in Q2 2026.
Outlook remains positive due to structural advantages in North American nitrogen assets and long-term agricultural demand, but risks include cyclical earnings, sulfur cost pressures, and volume constraints. The current price above the $76.17 consensus target suggests limited near-term upside, requiring monitoring of Q3 2026 results and cost management.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
